Precision BioSciences, Inc. (DTIL)
| Market Cap | 747.47M |
| Revenue (ttm) | 21.96M |
| Net Income (ttm) | -106.47M |
| Shares Out | 52.35M |
| EPS (ttm) | -2.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $13.29 |
| Previous Close | $13.58 |
| Change ($) | -0.29 |
| Change (%) | -2.14% |
| Day's Open | 13.64 |
| Day's Range | 12.85 - 13.70 |
| Day's Volume | 1,787,682 |
| 52-Week Range | 4.65 - 14.64 |
The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.
Cocrystal Pharma (NASDAQ: COCP) shares are trading higher after the company announced it has completed all research obligations under the Merck exclusive worldwide license and collaboration ag...
Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected to begin by mid-2021 Phase 1 clinical trial of PBCAR19B for patients with relapsed/refractory NHL expected...
DURHAM, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary AR...
DTIL has three business lines, all of which include important collaborations with large companies. Recent results in CAR-T therapies have been very encouraging.
DURHAM, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARC...
Acceptable Toler ability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS) , and No Grade ≥ 3 Neurotoxicity (ICANS)
DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary AR...
Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement
INDIANAPOLIS, and DURHAM, N.C., Nov. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and excl...
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 26.47% and 73.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for...
Shares of Precision BioSciences (NASDAQ:DTIL) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 21.95% year over year to ($0.50), which ...
Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary AR...
Precision Bio: 2020 Is Not Looking Great With 2 Terminated Partnerships And Cash Down -30% To $127M.
Precision BioSciences, Inc. is a life sciences company focused on utilizing its ARCUS genome editing platform to primarily treat human diseases and secondarily to provide food/agricultural sol...
PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings
DURHAM, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction thera...
DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction th...
Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Ta...
A key update from the U.S. Food and Drug Administration (FDA) boosted Precision BioSciences Inc.
DURHAM, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary...
DURHAM, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary...
DURHAM, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ...
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -5.00% and -80.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the...
Shares of Precision BioSciences (NASDAQ:DTIL) were unchanged after the company reported Q2 results.
Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ...
DURHAM, N.C., July 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ...
-PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic –
Shares of Precision BioSciences (NASDAQ:DTIL) rose 8.2% in pre-market trading after the company reported Q1 results.
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 1.89% and 34.71%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the ...
Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These healthcare stocks are risky, but they offer investors much better wealth-building potential than penny stocks.
DURHAM, N.C., April 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, pr...
PBCAR20A targets CD20 and is the Company’s second investigational allogeneic CAR T candidate advanced to the clinic
DURHAM, N.C., March 11, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, pr...
Precision BioSciences: Consider Taking Up A Small Position
Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
-Phase 1 clinical trial of off-the-shelf (allogeneic) anti-BCMA CAR T therapy candidate for patients with relapsed/refractory multiple myeloma expected to begin dosing patients in 2020-
Precision BioSciences Makes Impressive Progress On Mission To Change CAR-T Therapy Landscape
Find out why one of these stocks lost more than half its value.
Investors should remember that CRISPR isn't the only gene editing technology out there. Case in point: ARCUS.
Precision BioSciences provided an expanded update from its first clinical asset. Investors weren't impressed.
The American Society of Hematology's 61st annual meeting is underway in Orlando, Florida.
Shares of Precision BioSciences Inc. are up 13% in premarket trading after it announced positive results from a small Phase 1 clinical trial for its chimeric antigen receptor (CAR) T cell the...
- PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease-
As of late, it has definitely been a great time to be an investor in Precision BioSciences, Inc. (DTIL).
About DTIL
Precision BioSciences, a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for ac... [Read more...]
| Industry Biotechnology | IPO Date Mar 28, 2019 |
| CEO Matthew Kane | Employees 223 |
| Stock Exchange NASDAQ | Ticker Symbol DTIL |
Financial Performance
In 2019, DTIL's revenue was $22.24 million, an increase of 104.34% compared to the previous year's $10.88 million. Losses were -$92.88 million, 101.7% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for DTIL stock is "Buy." The 12-month stock price forecast is 15.57, which is an increase of 17.16% from the latest price.